Connecticut Seal

General Assembly

File No. 107

    January Session, 2013

Senate Bill No. 465

Senate, March 25, 2013

The Committee on Public Health reported through SEN. GERRATANA of the 6th Dist., Chairperson of the Committee on the part of the Senate, that the bill ought to pass.

This act shall take effect as follows and shall amend the following sections:

Section 1

October 1, 2013

19a-55(a)

PH

Joint Favorable

 

Agency Affected

Fund-Effect

FY 14 $

FY 15 $

Public Health, Dept.

GF - Cost

392,551

190,068

State Comptroller - Fringe Benefits1

GF - Cost

31,104

41,471

General Fund - TOTAL COST

423,655

231,539

Public Health, Dept.

GF - Potential Revenue Gain

423,655

231,539

POTENTIAL STATE FISCAL IMPACT

0

0

Item

FY 14 $1

FY 15 $

2 Chemists

90,051

120,068

Other Expenses (testing supplies)

52,500

70,000

Equipment (instrumentation)

250,000

-

Department of Public Health Costs

392,551

190,068

State Comptroller - Fringe Benefits Costs

31,104

41,471

STATE TOTAL

423,655

231,539

Possible newborn screening fee increase2

10.09

5.51

Potential General Fund revenue3

423,655

231,539

POTENIAL STATE FISCAL IMPACT

-

-

1SB 465 is effective 10/1/13. Position and testing supply costs reflect nine months of the fiscal year.

2Per CGS Sec. 19a-55, DPH has the authority to set the fee associated with newborn screening. This increase would raise the fee to $66.09 in FY 14 and $61.51 in FY 15 per newborn.

3Assumes 42,000 newborns born in Connecticut annually.

Sources:

2/27/13 Public Health Committee Testimony

 

State of New Jersey's Office of Legislative Services 1/14/13 fiscal estimate on screening newborn infants for adrenoleukodystrophy

Yea

28

Nay

0

(03/11/2013)

TOP

1 The fringe benefit costs for most state employees are budgeted centrally in accounts administered by the Comptroller. The estimated active employee fringe benefit cost associated with most personnel changes is 34.54% of payroll in FY 14 and FY 15.

2 Total revenue generated from the newborn screening fee was $2.5 million in FY 12. Of this, per Sec. 39 of PA 11-48, $1.1 million was authorized for use by DPH to pay for expenses incurred to perform the testing. The remainder ($1.4 million) was deposited into the General Fund as unrestricted revenue.

3 http://www.hrsa.gov/advisorycommittees/mchbadvisory/heritabledisorders/recommendedpanel/index.html